Abstract
Epstein - Barr virus - associated Diseases in Allogeneic Hematopoietic Stem Cell Transplantation
Highlights
According to the data of the European Group for Blood and Marrow Transplantation (EBMT) [11], RQ-PCR monitoring of Epstein - Barr virus (EBV)-DNA of blood in 73% transplant center has become a routine method for identifying HSCT recipients at risk for developing EBV-associated disease, diagnosis, preemptive therapy and therapeutic evaluation
EBV-DNA loads of blood are acted as the main basis for diagnosis, preemptive therapy and therapeutic evaluation, but our study and others cases reports [12,13] showed that special EBV-associated disease in central nervous system (CNS) and pulmonary had the discrepancy in EBV-DNA loads; sometimes repeated testing with real-time PCR in peripheral blood failed to show any evidence of EBV reactivation, and the change of EBVDNA loads of blood was inconsistent with disease development
EBV-DNA monitoring of blood was a routine method for diagnosis of post-transplant lymphoproliferative diseases (PTLD) and acted as an important indicator for preemptive therapy and therapeutic evaluation
Summary
Epstein - Barr virus (EBV) is a gamma - herpes virus that infects more 90% of humans. Except for lymph nodes, EBV can involve most other tissues and organs in recipients of transplants, and isolated central nervous system (CNS) involvement with PTLD is considered to be an exceedingly rare complication after alloHSCT [10]. According to the data of the European Group for Blood and Marrow Transplantation (EBMT) [11], RQ-PCR monitoring of EBV-DNA of blood in 73% transplant center has become a routine method for identifying HSCT recipients at risk for developing EBV-associated disease, diagnosis, preemptive therapy and therapeutic evaluation.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
